针对患者和提供者的健康系统嵌入减处方干预以预防老年人跌倒(STOP-FALLS试验):实用性整群随机对照试验的研究方案
STOP-FALLS试验是一项在Kaiser Permanente Washington开展的实用性整群随机对照试验,旨在测试针对中枢神经系统活性药物的健康系统嵌入减处方干预对社区老年人医疗治疗跌倒发生率的效果。干预包括向服用目标药物的老年人邮寄教育手册和自助材料,并向其初级保健提供者提供决策支持,主要结局为首次医疗治疗跌倒。
要点
- 干预为12个月减处方干预,包括邮寄教育手册和自助材料及提供者决策支持。
- 主要结局为基線后首次医疗治疗跌倒,样本量确保80%把握度检测20%的率降低。
- 目标药物包括60岁以上使用的阿片类、苯二氮䓬类和Z类药物,65岁以上使用的骨骼肌松弛剂、三环类抗抑郁药和抗组胺药。
核心结论
- STOP-FALLS试验将提供新信息,说明针对老年参与者及其初级保健提供者的健康系统嵌入减处方干预是否减少医疗治疗跌倒和中枢神经系统活性药物使用。
研究设计与样本
- 实用性、整群随机、平行组、对照临床试验,在Kaiser Permanente Washington开展,比较干预诊所(n=9)与常规护理诊所(n=9)。
- 干预为12个月减处方干预,包括向服用一种或多种中枢神经系统活性药物的老年人邮寄教育手册和自助材料,并向其初级保健提供者提供决策支持。
- 结局在干预后18-26个月期间检查,主要结局为基線后首次医疗治疗跌倒,样本量计算确保至少80%把握度检测医疗治疗跌倒率的20%降低,假设随访18个月。
主要发现
- 主要结局为首次事件(基線后)医疗治疗跌倒,根据健康计划数据确定。
- 次要结局包括任何目标药物的停药或剂量减少。
- 安全性结局包括严重药物戒断不良事件、非故意过量和死亡。
- 还将检查药物signetur字段以了解尝试减少药物的情况。
- 将报告影响干预实施的因素。
关键数值与推荐
- 目标药物:60岁及以上使用阿片类、苯二氮䓬类和Z类药物;65岁及以上使用骨骼肌松弛剂、三环类抗抑郁药和抗组胺药。
- 样本量计算确保至少80%把握度检测医疗治疗跌倒率的20%降低,假设随访18个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 试验注册为回顾性注册(retrospectively registered)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Central nervous system (CNS) active medications have been consistently linked to falls in older people. However, few randomized trials have evaluated whether CNS-active medication reduction reduces falls and fall-related injuries. The objective of the Reducing CNS-active Medications to Prevent Falls and Injuries in Older Adults (STOP-FALLS) trial is to test the effectiveness of a health-system-embedded deprescribing intervention focused on CNS-active medications on the incidence of medically treated falls among community-dwelling older adults. METHODS: We will conduct a pragmatic, cluster-randomized, parallel-group, controlled clinical trial within Kaiser Permanente Washington to test the effectiveness of a 12-month deprescribing intervention consisting of (1) an educational brochure and self-care handouts mailed to older adults prescribed one or more CNS-active medications (aged 60 + : opioids, benzodiazepines and Z-drugs; aged 65 + : skeletal muscle relaxants, tricyclic antidepressants, and antihistamines) and (2) decision support for their primary health care providers. Outcomes are examined over 18-26 months post-intervention. The primary outcome is first incident (post-baseline) medically treated fall as determined from health plan data. Our sample size calculations ensure at least 80% power to detect a 20% reduction in the rate of medically treated falls for participants receiving care within the intervention (n = 9) versus usual care clinics (n = 9) assuming 18 months of follow-up. Secondary outcomes include medication discontinuation or dose reduction of any target medications. Safety outcomes include serious adverse drug withdrawal events, unintentional overdose, and death. We will also examine medication signetur fields for attempts to decrease medications. We will report factors affecting implementation of the intervention. DISCUSSION: The STOP-FALLS trial will provide new information about whether a health-system-embedded deprescribing intervention that targets older participants and their primary care providers reduces medically treated falls and CNS-active medication use. Insights into factors affecting implementation will inform future research and healthcare organizations that may be interested in replicating the intervention. TRIAL REGISTRATION: ClinicalTrial.gov NCT05689554. Registered on 18 January 2023, retrospectively registered.
引用
- Balderson BH, Gray SL, Fujii MM, et al. A health-system-embedded deprescribing intervention targeting patients and providers to prevent falls in older adults (STOP-FALLS trial): study protocol for a pragmatic cluster-randomized controlled trial. Trials. 2023. PMID: 37170329. doi:10.1186/s13063-023-07336-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。